The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Stepanov I.A.

Irkutsk State Medical University

Sorokovikov V.A.

Irkutsk Research Center of Surgery and Traumatology

beloborodov V.A.

Irkutsk State Medical University

Krivoshapkin A.L.

People’s Friendship University of Russia

Gaitan A.S.

People’s Friendship University of Russia

Shameeva M.A.

Irkutsk State Medical University

Modern advances in molecular and cellular biology in the treatment of glioblastoma

Authors:

Stepanov I.A., Sorokovikov V.A., beloborodov V.A., Krivoshapkin A.L., Gaitan A.S., Shameeva M.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(4): 66‑72

DOI: 10.17116/onkolog20221104166

Read: 1877 times

Download PDF (RU)
Contact the author
Table of contents

MODERN ADVANCES IN MOLECULAR AND CELLULAR BIOLOGY IN THE TREATMENT OF GLIOBLASTOMA
MODERN ADVANCES IN MOLECULAR AND CELLULAR BIOLOGY IN THE TREATMENT OF GLIOBLASTOMA

To cite this article:

Stepanov IA, Sorokovikov VA, beloborodov VA, Krivoshapkin AL, Gaitan AS, Shameeva MA. Modern advances in molecular and cellular biology in the treatment of glioblastoma. P.A. Herzen Journal of Oncology. 2022;11(4):66‑72. (In Russ.)
https://doi.org/10.17116/onkolog20221104166

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Anti­gen rece­ptors in the deve­lopment of CAR-T cells for glioblastoma immu­notherapy. P.A. Herzen Journal of Onco­logy. 2024;(6):91-95
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
Radiation therapy with focal dose esca­lation in the treatment of glioblastoma. P.A. Herzen Journal of Onco­logy. 2025;(2):64-69
A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model. Burdenko's Journal of Neurosurgery. 2024;(6):54-62
Modern concepts of preeclampsia, taking into account the role of the permeability of the hema­toencephalic barrier. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):11-18
The effect of Mexi­dol on the level of neurogenesis markers in acute cere­brovascular acci­dent in the expe­riment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118
TERTp muta­tion screening using digi­tal droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95
Abstract:

Gliomas are the most common group of primary brain tumors, accounting for at least 80% of all types of central nervous system neoplasias. High-grade gliomas (anaplastic astrocytoma and oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, as well as three molecular genetic subtypes of glioblastomas) deserve special attention due to a poor prognosis for patient survival. A search for literature sources in the Russian and foreign databases has demonstrated that there are few studies of new treatments for high-grade gliomas, including glioblastomas. Combining the results of these studies has been an impetus to write this literature review.

Keywords:

high-grade gliomas
glioblastoma
immune therapy
vaccine therapy
molecular targeted therapy
blood-brain barrier

Authors:

Stepanov I.A.

Irkutsk State Medical University

Sorokovikov V.A.

Irkutsk Research Center of Surgery and Traumatology

beloborodov V.A.

Irkutsk State Medical University

Krivoshapkin A.L.

People’s Friendship University of Russia

Gaitan A.S.

People’s Friendship University of Russia

Shameeva M.A.

Irkutsk State Medical University

Received:

08.09.2021

Accepted:

06.10.2021

Close metadata

References:

  1. Stepanov IA, Beloborodov VA, Shameeva MA, Borisov EB, Shagdurova IA. Application of the measured diffusion coefficient in predicting overall survival and progression-free survival in patients with recurrent glioblastoma treated with bevacizumab. Oncology. Journal im. P.A. Herzen= Onkologiya. Zhurnal im. P.A. Gertsena. 2020;9(6):51-58. (In Russ.). https://doi.org/10.17116/onkolog2020906151
  2. Goryainov SA, Goldberg MF, Golanov AV, Zolotova SV, Shishkina LV, Ryzhova MV, Pitskhelauri DI, Zhukov VYu, Usachev DYu, Belyaev AYu, Kondrashov AV, Shurkhai VA, Potapov AA. The phenomenon of long-term survival of patients with glioblastomas. Part I: the role of clinical and demographic factors and the IDH1 mutation (R132H). Burdenko’s Journal of Neurosurgery=Voprosy Neirokhirurgii im. N.N. Burdenko. 2017;81(3):5-16. (In Russ.). https://doi.org/10.17116/neiro20178135-16
  3. Potapov AA, Goryainov SA, Okhlopkov VA, Pitskhelauri DI, Kobyakov GL, Zhukov VYu, Gol’bin DA, Svistov DV, Martynov BV, Krivoshapkin AL, Gaitan AS, Anokhina YuE, Varyukhina MD, Goldberg MF, Kondrashov AV, Chumakova AP. Clinical guidelines for the use of intraoperative fluorescence diagnostics in brain tumor surgery. Burdenko’s Journal of Neurosurgery=Voprosy Neirokhirurgii im. N.N. Burdenko. 2015;79(5):91-101. (In Russ.). https://doi.org/10.17116/neiro201579591-101
  4. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820.  https://doi.org/10.1007/s00401-016-1545-1
  5. Zhang X, Zhang W, Mao XG, Cao WD, Zhen HN, Hu SJ. Malignant intracranial high grade glioma and current treatment strategy. Curr Cancer Drug Targets. 2019;19(2):101-108.  https://doi.org/10.2174/1568009618666180530090922
  6. Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-397.  https://doi.org/10.1016/B978-0-12-802997-8.00023-2
  7. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-1850. https://doi.org/10.1001/jama.2013.280319
  8. Roth P, Gramatzki D, Weller M. Management of elderly patients with glioblastoma. Curr Neurol Neurosci Rep. 2017;17(4):35.  https://doi.org/10.1007/s11910-017-0740-3
  9. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772.  https://doi.org/10.1158/1078-0432.CCR-12-3002
  10. Chavda V, Patel V, Yadav D, Shah J, Patel S, Jin JO. Therapeutics and research related to glioblastoma: advancements and future targets. Curr Drug Metab. 2020;21(3):186-198.  https://doi.org/10.2174/1389200221666200408083950
  11. Grech N, Dalli T, Mizzi S, Meilak L, Calleja N, Zrinzo A. Rising incidence of glioblastoma multiforme in a well-defined population. Cureus. 2020;12(5):e8195. https://doi.org/10.7759/cureus.8195
  12. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12 suppl 2):iv1-iv96. https://doi.org/10.1093/neuonc/noaa200
  13. Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncology. 2018;4(9):1254-1262. https://doi.org/10.1001/jamaoncol.2018.1789
  14. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299-312.  https://doi.org/10.3322/caac.21613
  15. Rushing EJ. WHO classification of tumors of the nervous system: preview of the upcoming 5th edition. MEMO. 2021;14(suppl 2):188-191.  https://doi.org/10.1007/s12254-021-00680-x
  16. Penas-Prado M. Practice-changing abstracts from the 2016 Society for Neuro-Oncology Annual Scientific Meeting. Am Soc Clin Oncol Educ Book. 2017;37:187-191.  https://doi.org/10.1200/EDBK_175563
  17. Fiani B, Covarrubias C, Onyedimma C, Jarrah R. Neurocytological advances in the treatment of glioblastoma multiforme. Cureus. 2021;13(7):e16301. https://doi.org/10.7759/cureus.16301
  18. Bostian AC, Maddukuri L, Reed MR, Savenka T, Hartman JH, Davis L, Pouncey DL, Miller GP, Eoff RL. Kynurenine signaling increases DNA polymerase kappa expression and promotes genomic instability in glioblastoma cells. Chem Res Toxicol. 2016;29(1):101-108.  https://doi.org/10.1021/acs.chemrestox.5b00452
  19. Doherty GJ, de Paula BHR. Cannabinoids in glioblastoma multiforme — hype or hope? Br J Cancer. 2021;124(8):1341-1343. https://doi.org/10.1038/s41416-021-01265-5
  20. Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324.  https://doi.org/10.3390/biomedicines9030324
  21. Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018;20(12):1566-1572. https://doi.org/10.1093/neuonc/noy072
  22. Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo). 2018;58(10):405-421.  https://doi.org/10.2176/nmc.ra.2018-0141
  23. Shah JL, Li G, Shaffer JL, Azoulay MI, Gibbs IC, Nagpal S, Soltys SG. Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma. Neurosurgery. 2018;82(1):24-34.  https://doi.org/10.1093/neuros/nyx115
  24. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-1850. https://doi.org/10.1001/jama.2013.280319
  25. Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR. A review on Tumor-Treating Fields (TTFields): clinical implications inferred from computational modeling. IEEE Rev Biomed Eng. 2018;11:195-207.  https://doi.org/10.1109/RBME.2017.2765282
  26. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. https://doi.org/10.1001/jama.2017.18718
  27. Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma — an update. Crit Rev Oncolol Hematol. 2016;99:389-408.  https://doi.org/10.1016/j.critrevonc.2016.01.018
  28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.  https://doi.org/10.1126/science.1104819
  29. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954-1963. https://doi.org/10.1056/NEJMoa1707358
  30. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw. 2011;9(4):403-407.  https://doi.org/10.6004/jnccn.2011.0037
  31. Lombardi G, Pambuku A, Bellu L, Farina M, Della Puppa A, Denaro L, Zagonel V. Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncolol Hematol. 2017;111:94-102.  https://doi.org/10.1016/j.critrevonc.2017.01.018
  32. Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev. 2020;5(5):CD013238. https://doi.org/10.1002/14651858.CD013238.pub2
  33. Jiménez-Alcázar M, Curiel-García Á, Nogales P, Perales-Patón J, Schuhmacher AJ, Galán-Ganga M, Zhu L, Lowe SW, Al-Shahrour F, Squatrito M. Dianhydrogalactitol overcomes multiple temozolomide resistance mechanisms in glioblastoma. Mol Cancer Ther. 2021;20(6):1029-1038. https://doi.org/10.1158/1535-7163.MCT-20-0319
  34. Ellert-Miklaszewska A, Ciechomska IA, Kaminska B. Cannabinoid signaling in glioma cells. Adv Exp Med Biol. 2020;1202:223-241.  https://doi.org/10.1007/978-3-030-30651-9_11
  35. Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130(9):1132-1143. https://doi.org/10.1182/blood-2016-11-752840
  36. Wahba A, Rath BH, O’Neill JW, Camphausen K, Tofilon PJ. The XPO1 inhibitor selinexor inhibits translation and enhances the radiosensitivity of glioblastoma cells grown in vitro and in vivo. Mol Cancer Ther. 2018;17(8):1717-1726. https://doi.org/10.1158/1535-7163.MCT-17-1303
  37. Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85.  https://doi.org/10.1186/s13045-014-0085-1
  38. Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jackson C, Peterson J, Trifiletti D, Hammack J, Ortiz K, Lesser E, et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol. 2020;147(2):297-307.  https://doi.org/10.1007/s11060-020-03451-6
  39. Xu LW, Chow KK, Lim M, Li G. Current vaccine trials in glioblastoma: a review. J Immunol Res. 2014;2014:796856. https://doi.org/10.1155/2014/796856
  40. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12(2):259-266.  https://doi.org/10.1023/a:1008382516636
  41. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67.  https://doi.org/10.1186/1479-5876-5-67
  42. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19(1):205-214.  https://doi.org/10.1158/1078-0432.CCR-11-3358
  43. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-525.  https://doi.org/10.1158/1078-0432.CCR-05-0464
  44. Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, Hentati D, Guedes de Castro D, Dyttus-Cebulok K, Drodge S, et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(35):4145-4150. https://doi.org/10.1200/JCO.2015.62.6606
  45. Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X. Advances in immunotherapy for glioblastoma multiforme. J Immunol Res. 2017;2017:3597613. https://doi.org/10.1155/2017/3597613
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.